Company intelligence / Profile preview

JND Therapeutics

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

JND Therapeutics is a South Korean biotechnology company focused on developing innovative small molecule therapeutics for neurodegenerative diseases and oncology. The company leverages its proprietary drug discovery platform to target key biological pathways involved in protein aggregation and cellular signaling. Its lead program, JND-3204, is being developed as a potent and selective inhibitor of LRRK2 for the treatment of Parkinson's disease. JND Therapeutics aims to address significant unmet medical needs through the development of brain-penetrant and highly specific chemical entities. The company is supported by prominent Korean venture capital firms and is advancing its pipeline toward clinical trials.

Therapeutic areas: OncologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on JND Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JND Therapeutics.

Explore the full profile